Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bionomics Ltd BNOX

Healthcare Biotechnology
Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its... see more

Recent & Breaking News (NDAQ:BNOX)

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

GlobeNewswire November 8, 2024

Bionomics to Present at the 2024 CNS Summit

GlobeNewswire November 7, 2024

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program

GlobeNewswire November 4, 2024

Bionomics to Present at the ThinkEquity Conference

GlobeNewswire October 23, 2024

Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

GlobeNewswire October 14, 2024

Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

GlobeNewswire October 7, 2024

Bionomics Limited announces intention to re-domicile to the United States

GlobeNewswire October 1, 2024

Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

GlobeNewswire July 31, 2024

Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

GlobeNewswire July 29, 2024

Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

GlobeNewswire July 18, 2024

Bionomics Limited Announces Private Placement of up to $70.0 Million

GlobeNewswire May 31, 2024

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

GlobeNewswire May 20, 2024

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

GlobeNewswire March 21, 2024

Bionomics to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire February 22, 2024

Bionomics Provides a Review of 2023 and of 2024 Plans

GlobeNewswire January 22, 2024

Bionomics to Present at Biotech Showcase(TM) 2024

GlobeNewswire January 5, 2024

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

GlobeNewswire December 6, 2023

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

GlobeNewswire October 16, 2023

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

GlobeNewswire September 28, 2023